3415A 3 Ave NW, Calgary, Alberta, T2N 0M4, Canada

Patient Name: PATIENT, NAME
Specimen ID (SID): 26001-0000-06
DOB: 01-Jan-2000
PHN: AB 00000000
Reason for Testing: Refractory arthritis
Relevant Medications: -

External SID: 123456789
Doctor: Dr. Doctor
Report Date: 01-Apr-2026

Specimen Type: Plasma
Date/Time Collected: 01-Jan-2026 / 00:00

Interferon Panel

Laboratory Developed Test (LDT)

Analyte	Results (pg/ml)		Reference Interval†
TYPE I INTERFERONS			
IFNα2	153	**HIGH**	13 - 128
IFNβ	169	**HIGH**	0 - 99.1
IFNω	96.8	**HIGH**	0 - 55.7
TYPE II INTERFERONS			
IFNγ	3.8		0 - 8.3
TYPE III INTERFERONS			
IFNλ1	44.5	**HIGH**	0 - 31.8
IFNλ2	43.5	**HIGH**	0 - 42.5
INTERFERON-RESPONSIVE CHEMOKINES			
I-TAC	76.0		9 - 289
IP-10	379	**HIGH**	21 - 281
MIG	8365	**HIGH**	381 - 5907

Sample Comments:

-

Results Interpretation:

- High IFNα2, IFNβ, and IFNω suggest activation of Type I interferon-driven antiviral programs, which could indicate induction of interferon-stimulated gene expression and promotion of broad antiviral and myeloid-activating signaling.
- High IFNλ1 and IFNλ2 suggest mucosal- or barrier-focused interferon signaling, which may reflect epithelial antiviral responses that influence local barrier immunity.
- High IP-10 and MIG suggest interferon-responsive chemokine activity, consistent with chemokine-mediated recruitment of CXCR3-expressing leukocytes and coordination of interferon-driven immune cell trafficking.

Disclaimer:

The interpretation of these test results should be correlated with clinical findings and other diagnostic tests. Biomarker levels can vary due to many biological, physiological, and diurnal factors; their clinical significance must be assessed by a qualified healthcare professional. This information is not intended to be used as the sole basis for diagnosis or treatment decisions.

Reviewed by: DP
Eve Technologies Corporation is a CLIA certified High Complexity International Laboratory
† Reference intervals estimated by data-mining ≥2000 PLASMA samples drawn from both healthy and pathological subjects.